1-7 of 7
Martine J. Piccart
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PS11-09: Impact of UGT1A1 status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer

Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O'Shaughnessy, Javier Cortés, Véronique Diéras, Lisa Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS11-09.
https://doi.org/10.1158/1538-7445.SABCS20-PS11-09
Published: 15 February 2021
View article titled, Abstract PS11-09: Impact of <em>UGT1A1</em> status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer
Journal Articles

Abstract GS4-05: Should age be integrated together with clinical and genomic risk for adjuvant chemotherapy decision in early luminal breast cancer? MINDACT results compared to those of TAILOR-X

Martine J Piccart, Coralie Poncet, Fatima Cardoso, Laura van't Veer, Suzette Delaloge, Jean-Yves Pierga, Etienne Brain, Suzan Vrijaldenhoven, P.A. Neijenhuis, Kim Aalders, Emiel Rutgers
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): GS4-05.
https://doi.org/10.1158/1538-7445.SABCS19-GS4-05
Published: 15 February 2020
View article titled, Abstract GS4-05: Should age be integrated together with clinical and genomic risk for adjuvant chemotherapy decision in early luminal breast cancer? MINDACT results compared to those of TAILOR-X
Journal Articles

Abstract P4-01-01: Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial

Minetta C Liu, Brigitte Rack, Amylou C Dueck, David W Hillman, Michael B Campion, Monica M Reinholz, Kevin C Halling, Christos Sotiriou, Françoise Rothé, Marion Maetens, Ghizlane Rouas, Wolfgang Janni, Antonio C Wolff, Lyndsay N Harris, Julie R Gralow, Kathleen I Pritchard, Susan Ellard, Nguyet A Le-Lindqwister, Frances Boyle, Evandro De Azambuja, Martine J Piccart-Gebhart, Michail Ignatiadis, Edith A Perez
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P4-01-01.
https://doi.org/10.1158/1538-7445.SABCS14-P4-01-01
Published: 01 May 2015
View article titled, Abstract P4-01-01: Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial
Journal Articles

Abstract P4-11-08: Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) vs clinical subtypes for breast cancer, among 6,694 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial

Giuseppe Viale, Leen Slaets, Femke A de Snoo, Jan Bogaerts, Laura J van 't Veer, Emiel J Rutgers, Martine J Piccart-Gebhart, Jeroen van den Akker, Lisette Stork-Sloots, Leila Russo, Patrizia Dell'Orto, Fatima Cardoso
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P4-11-08.
https://doi.org/10.1158/1538-7445.SABCS14-P4-11-08
Published: 01 May 2015
View article titled, Abstract P4-11-08: Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) vs clinical subtypes for breast cancer, among 6,694 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial
Journal Articles

Abstract SY45-02: Evaluation of targeted therapies in advanced breast cancer

Martine J. Piccart
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): SY45-02.
https://doi.org/10.1158/1538-7445.AM2014-SY45-02
Published: 01 October 2014
View article titled, Abstract SY45-02: Evaluation of targeted therapies in advanced breast cancer
Journal Articles

Why Your Preferred Targeted Drugs May Become Unaffordable

Martine J. Piccart
Journal: Cancer Research
Cancer Res (2013) 73 (19): 5849–5851.
https://doi.org/10.1158/0008-5472.CAN-13-1486
Published: 01 October 2013
View article titled, Why Your Preferred Targeted Drugs May Become Unaffordable
Open the PDF for Why Your Preferred Targeted Drugs May Become Unaffordable in another window
Journal Articles

Abstract PL01-02: The Breast International Group (BIG): Building on an accelerated path to tailored adjuvant cancer therapy

Martine J. Piccart-Gebhart
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): PL01-02.
https://doi.org/10.1158/1538-7445.AM10-PL01-02
Published: 15 April 2010
View article titled, Abstract PL01-02: The Breast International Group (BIG): Building on an accelerated path to tailored adjuvant cancer therapy